… change from baseline in pre-bronchodilator FEV 1 at week 12. … to week 12 in pre-bronchodilator
FEV 1 . Additional lung … 75%, post-bronchodilator FEV 1 , and post-bronchodilator slope …

… achievable bronchodilation, whereas serial doses of albuterol … blind, randomly ordered,
parallel-group study design, we found … manner to a comparable group of patients. The superior …

… was included to patients' established background COPD therapy, for example, daily ICS.
The short-acting bronchodilator salbutamol (albuterol) was provided for rescue use throughout …

… with bronchodilator therapy in most COPD patients. … , parallel group studies that were
conducted to evaluate the long-term efficacy and safety of ipratropium combined with albuterol in a …

… bronchodilation than single drugs alone. In two randomized, double-blind, parallel-group, …
As a result, they are likely to be on more than one bronchodilator therapy to treat airflow …

… , placebo-controlled, parallel-group, Phase III studies investigated … The first available
long-acting bronchodilators (such as the … More recently, bronchodilators with a longer duration of …

… , placebo-controlled, parallel-group trial in patients with COPD (… 12 in all groups receiving
SMBM plus bronchodilator therapy … in the groups receiving SMBM plus bronchodilator therapy …

… This randomized, double-blind, double-dummy, parallel-group trial compared the efficacy …
has been observed previously with inhaled bronchodilator therapy. Similarly, the improvement …

… bronchodilator therapy. At the start of the four-year study, patients were randomly assigned
to one of two parallel treatment groups… ) between the two parallel treatment groups was 40 ml …

… Combination bronchodilator therapy for chronic obstructive … the effectiveness of an
albuterol-ipratropium solution aerosol … in an 8-week parallel-group experience in which to …